Selective BH3-mimetic antagonists have been developed for BCL-XL (including A-1331852, A-1155463 and WEHI-539) and MCL-1 (S63845), thereby driving cell death in BCL-XL- and MCL-1-dependent cancer cells [15, 16]. Here, BCL2L1 is linked to cancer.